http://online.wsj.co...925-904896.html
" SL-401 significantly reduced the growth of CML blasts, as well as CSCs, from patients with tyrosine kinase inhibitor (TKI)-resistant CML. In addition, the combination of SL-401 and the TKI, imatinib (Gleevec), had a significant synergistic effect on inhibiting the growth of primary CML cells from patients. SL-401 also prolonged the survival of mice inoculated with primary cells from a CML patient in blast crisis who was resistant to several TKIs."
Comments?